Brandon Capital, Australasia’s leading life sciences venture capital firm, today announces the successful exit of its portfolio company Myricx Bio following its agreement to be acquired by Novartis.

Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exit The proposed acquisition combines the oncology expertise of Novartis with ...

Indiana is home to many outstanding high schools that consistently prepare students for college, careers, and lifelong ...

Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...

India’s ICCR scholarship programme will soon travel to India to pursue their studies, where they will experience independent ...